Filing Flows › Evofem Biosciences (EVFM) › Q2 2026 › vs Q2 2025
Evofem Biosciences (EVFM) Q2 2026 vs Q2 2025 (year over year)
Evofem Biosciences's revenue fell $2.2M (-45%) from $4.8M in Q2 2025 to $2.6M in Q2 2026.
Evofem Biosciences, Q2 2026: revenue $2.6M (-45% year over year), operating margin -94.5%, net loss $11.0M, operating cash flow −$3.1M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $2.6M | $4.8M | −$2.2M | -45% |
| Net loss | $11.0M | $1.8M | $9.3M | +519% |
| Costs & expenses | $13.7M | $6.6M | $7.1M | +107% |
| Operating costs | $5.1M | $6.1M | −$954K | -16% |
| Interest & other, net | $8.5M | $526K | $8.0M | 16× |
| Cost of revenue | $511K | $755K | −$244K | -32% |
| Sales & marketing | $2.1M | $2.6M | −$550K | -21% |
| General & admin | $1.8M | $1.8M | −$15K | -0.8% |
| Other operating costs | $708K | $853K | −$145K | -17% |
| Operating cash sources | $11.0M | $1.8M | $9.3M | +530% |
| Depreciation & amortization | $18K | $111K | −$93K | -84% |
| Working capital & other | $7.9M | −$1.3M | $9.2M | — |
| Cash used in operations | $3.1M | $2.9M | $221K | +8% |
| Net loss absorbed | $11.0M | $1.8M | $9.3M | +519% |
Questions
How much did Evofem Biosciences's revenue grow year over year in Q2 2026?
Evofem Biosciences's revenue fell $2.2M (-45%) from $4.8M in Q2 2025 to $2.6M in Q2 2026.